Pharmaceutical inhalation suspension has antimicrobial activity against at least one of Streptococcus pneumoniae, Hemophilus influenzae, and Staphylococcus aureus, comprises amoxicillin, clavulanate, chitosan, Poly(lactic-co-glycolic acid), N-Acetyl cysteine, Polysorbate 80, viscosity enhancer
	CHITYALA M; AMBATI S R
	2023-12-29
专利权人	AODH LIFESCIENCES PRIVATE LTD (AODH-Non-standard)
申请日期	2023-12-29
专利号	IN202341047810-A
成果简介	NOVELTY - Pharmaceutical inhalation suspension comprises: 0.5-7.5 wt.% amoxicillin; 0.1-5.0 wt.% clavulanate; 0.1-1 wt.% chitosan as a mucoadhesive polymer; 0.5-1.5 wt.% Poly(lactic-co-glycolic acid) (PLGA) with a lactide-to-glycolide ratio of 50:50 to 75:25; 0.05-0.1 wt.% N-Acetyl cysteine, as biofilm disruption agents; 0.05-0.1 wt.% surfactant, Polysorbate 80; and 0.1-0.5 wt.% viscosity enhancer, hydroxypropyl methylcellulose; and buffered saline to maintain a pH range of 6.1-7.2. USE - Pharmaceutical inhalation suspension has antimicrobial activity against at least one of Streptococcus pneumoniae, Hemophilus influenzae, and Staphylococcus aureus; for the treatment of severe or resistant respiratory infections (all claimed), and pneumonia. Test details are described but no results given. ADVANTAGE - The formulation remains stable for at least 3 months at room temperature conditions of 25℃; remains physically and chemically stable for at least 6 months; eliminates drug-resistant Streptococcus pneumoniae, Hemophilus influenzaeor other respiratory infections in the respiratory tract; minimizes systemic side effects, improves treatment efficacy, and address the growing challenge of antibiotic resistance in pneumonia; maintains physical stability, thus preventing phase separation and ensuring uniform distribution of the drug particles. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method of manufacturing a nebulization suspension comprising amoxicillin and clavulanic acid, comprising: providing amoxicillin and clavulanic acid; providing chitosan, poly(lactic-co-glycolic acid) (PLGA), N-acetylcysteine, and glycerol; combining amoxicillin, clavulanic acid, chitosan, PLGA, Nacetylcysteine, and glycerol with sterile water for injection to form a suspension; adjusting the pH of suspension to a physiologically acceptable range; sterile filtering said suspension; aseptically filling suspension into a suitable container; and sealing container.
IPC 分类号	A61K-009/20
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/18600
专题	中国科学院新疆生态与地理研究所
作者单位	AODH LIFESCIENCES PRIVATE LTD (AODH-Non-standard)
推荐引用方式 GB/T 7714	CHITYALA M,AMBATI S R. Pharmaceutical inhalation suspension has antimicrobial activity against at least one of Streptococcus pneumoniae, Hemophilus influenzae, and Staphylococcus aureus, comprises amoxicillin, clavulanate, chitosan, Poly(lactic-co-glycolic acid), N-Acetyl cysteine, Polysorbate 80, viscosity enhancer. IN202341047810-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。